A technology developer whose software is being used to manage clinical trials of potential coronavirus (COVID-19) vaccines has been hit by a ransomware attack, the New York Times reported.The cyber assault on eResearch Technology, a Philadelphia, Pennsylvania-based company that sells a digital platform for drug companies to manage seasonal and epidemic vaccine trials, began roughly two weeks ago, officials said. It’s unclear if any COVID-19 vaccine participants were affected by the cyber extortion.IQVIA, a researcher involved with AstraZeneca’s COVID-19 vaccine, and Bristol Myers Squibb, which is collaborating on a rapid test for the novel virus, were targeted by the cyber extortionists, according to reports. Both companies said the attacks were blunted by their data backups but other outfits were less prepared and forced to track trial patients manually, the NYT’s report said. In a statement, IQVIA said it was “not aware of any confidential data or patient information, related to our clinical trial activities, that have been removed, compromised or stolen.”As in most ransomware attacks, the perpetrators remain unknown. ERT did not disclose the nature of the hacker’s ransom demands or if it had met them. The ransomware crooks crippled ERT’s computer systems on September 20, when employees said they could not access data on their systems, Drew Bustos, ERT’s marketing vice president, told the NYT. The developer responded by taking its network down and bringing in security specialists to assess and help mitigate the damage. It's unclear if managed security service providers (MSSPs) are specifically involved in the investigation and recovery effort. ERT also notified the Federal Bureau of Investigation of the breach, he said.“Nobody feels great about these experiences, but this has been contained,” Bustos reportedly said. ERT is in the process of bringing its systems back online, he said.